NP1867 is a potent, selective, covalent PMS2 inhibitor. NP1867 functionally inhibits DNA mismatch repair. NP1867 enhances immune surveillance. NP1867 can be used in the research of colorectal cancer [1] [2].
References:
[1]. Blagg J, et al. Abstract C086: NP1867, a potent, selective, covalent small molecule inhibitor of DNA Mismatch Repair (MMR) protein PMS2, functionally inhibits MMR in cells and elicits COSMIC mutational signatures consistent with MMR-deficient patient samples. Molecular Cancer Therapeutics, 2023, 22(12_Supplement): C086-C086.
[2]. Piumatti E, et al. Pharmacological inhibition of PMS2 increases tumor mutational burden, induces microsatellite instability and elicits immune mediated rejection in vivo[J]. Cancer Research, 2024, 84(6_Supplement): 6011-6011.
References:
[1]. Blagg J, et al. Abstract C086: NP1867, a potent, selective, covalent small molecule inhibitor of DNA Mismatch Repair (MMR) protein PMS2, functionally inhibits MMR in cells and elicits COSMIC mutational signatures consistent with MMR-deficient patient samples. Molecular Cancer Therapeutics, 2023, 22(12_Supplement): C086-C086.
[2]. Piumatti E, et al. Pharmacological inhibition of PMS2 increases tumor mutational burden, induces microsatellite instability and elicits immune mediated rejection in vivo[J]. Cancer Research, 2024, 84(6_Supplement): 6011-6011.